These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 33064681)

  • 21. Cervical cancer in Tosamaganga Hospital, Tanzania: difficulties and challenges in a low resource country setting.
    Cola E; Maziku D; Torelli GF; Fagotti A
    Int J Gynecol Cancer; 2019 Oct; 29(8):1336-1337. PubMed ID: 31326948
    [No Abstract]   [Full Text] [Related]  

  • 22. Summary of the NIH Consensus Development Conference on Cervical Cancer.
    Oncology (Williston Park); 1997 May; 11(5):672, 674. PubMed ID: 9159793
    [No Abstract]   [Full Text] [Related]  

  • 23. Immunotherapy of cervical cancer as a biological dissipative structure.
    Klimek R; Klimek M; Jasiczek D
    Neuro Endocrinol Lett; 2011; 32(4):380-8. PubMed ID: 21876504
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Perspective for prophylaxis and treatment of cervical cancer: an immunological approach.
    Jenkins M; Chiriva-Internati M; Mirandola L; Tonroy C; Tedjarati SS; Davis N; D'Cunha N; Tijani L; Hardwick F; Nguyen D; Kast WM; Cobos E
    Int Rev Immunol; 2012 Feb; 31(1):3-21. PubMed ID: 22251005
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunotherapy and targeted therapy for cervical cancer: an update.
    Menderes G; Black J; Schwab CL; Santin AD
    Expert Rev Anticancer Ther; 2016; 16(1):83-98. PubMed ID: 26568261
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunotherapy using the streptococcal preparation OK-432 for the treatment of uterine cervical cancer. Cervical Cancer Immunotherapy Study Group.
    Noda K; Teshima K; Tekeuti K; Hasegawa K; Inoue K; Yamashita K; Sawaragi I; Nakajima T; Takashima E; Ikeuchi M
    Gynecol Oncol; 1989 Dec; 35(3):367-72. PubMed ID: 2689304
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Ⅲ.The Current Status and Future Perspective of Chemotherapy, Targeted Therapy and Immunotherapy for Cervical Cancer].
    Yabuno A; Hasegawa K
    Gan To Kagaku Ryoho; 2020 Feb; 47(2):242-246. PubMed ID: 32381956
    [No Abstract]   [Full Text] [Related]  

  • 28. Immunotherapy for cervical cancer: Can it do another lung cancer?
    Ramanathan P; Dhandapani H; Jayakumar H; Seetharaman A; Thangarajan R
    Curr Probl Cancer; 2018; 42(2):148-160. PubMed ID: 29500076
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Global strategies for cervical cancer control in the 21st century.
    Trimble T
    Gynecol Oncol; 2005 Dec; 99(3 Suppl 1):S245. PubMed ID: 16419215
    [No Abstract]   [Full Text] [Related]  

  • 30. Expression of tissue factor in adenocarcinoma and squamous cell carcinoma of the uterine cervix: implications for immunotherapy with hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor.
    Cocco E; Varughese J; Buza N; Bellone S; Glasgow M; Bellone M; Todeschini P; Carrara L; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Lockwood CJ; Santin AD
    BMC Cancer; 2011 Jun; 11():263. PubMed ID: 21693061
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The cancer patient - illustrated by cervical cancer].
    Stoll P
    Fortschr Med; 1976 Sep; 94(27):1433-4, 1487-8. PubMed ID: 971888
    [No Abstract]   [Full Text] [Related]  

  • 32. Cervical cancer screening and management, new challenges.
    Monsonego J
    Eur J Gynaecol Oncol; 1999; 20(5-6):352-4. PubMed ID: 10609492
    [No Abstract]   [Full Text] [Related]  

  • 33. Immunotherapy With Radiotherapy and Chemoradiotherapy for Cervical Cancer.
    Feng CH; Mell LK; Sharabi AB; McHale M; Mayadev JS
    Semin Radiat Oncol; 2020 Oct; 30(4):273-280. PubMed ID: 32828383
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Proceedings of the First Symposium on Cervical Cancer: challenging cervical cancer. Madrid, Spain. February 21-22, 2008.
    Gynecol Oncol; 2008 Sep; 110(3 Suppl 2):S1-80. PubMed ID: 18814346
    [No Abstract]   [Full Text] [Related]  

  • 35. Report on the 2007 International Workshop on Human Papillomaviruses and Consensus Recommendations for Cervical Cancer Prevention.
    Grce M; Davies P; Arbyn M; Anttila A; Grubisić G; Kardum-Skelin I; Herbert A; Jordan J; von Karsa L
    Cent Eur J Public Health; 2008 Mar; 16(1):38-40. PubMed ID: 18459479
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Practice guidelines for management of cervical cancer in Korea: a Korean Society of Gynecologic Oncology Consensus Statement.
    Lim MC; Lee M; Shim SH; Nam EJ; Lee JY; Kim HJ; Lee YY; Lee KB; Park JY; Kim YH; Ki KD; Song YJ; Chung HH; Kim S; Lee JW; Kim JW; Bae DS; Lee JM
    J Gynecol Oncol; 2017 May; 28(3):e22. PubMed ID: 28382794
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cancer of the cervix: prospects for immunological control.
    Davies DH; McIndoe GA; Chain BM
    Int J Exp Pathol; 1991 Apr; 72(2):239-51. PubMed ID: 1849733
    [No Abstract]   [Full Text] [Related]  

  • 38. Nivolumab in chemotherapy-resistant cervical cancer: report of a vulvitis as a novel immune-related adverse event and molecular analysis of a persistent complete response.
    Baettig F; Vlajnic T; Vetter M; Glatz K; Hench J; Frank S; Bihl M; Lopez R; Dobbie M; Heinzelmann-Schwarz V; Montavon C
    J Immunother Cancer; 2019 Oct; 7(1):281. PubMed ID: 31672171
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Results of working on the problem of cervical cancer within the framework of a goal-directed program].
    Shuvaeva NI; Starinskiĭ VV; Popova AA
    Sov Med; 1985; (10):53-7. PubMed ID: 2934826
    [No Abstract]   [Full Text] [Related]  

  • 40. Cervical cancer: summary of the NIH consensus.
    Rev Panam Salud Publica; 1997 Apr; 1(4):330-2. PubMed ID: 9149525
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.